Eyenovia

United States
Troy, New Hampshire, United States, 10017

Company profile

Eyenovia company profile

Eyenovia is a biopharmaceutical company that provides portfolio of next generation topical eye treatments. It is a clinical stage, ophthalmic biopharmaceutical company that transforms the delivery of therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. Eyenovia’s breakthrough piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing therapeutics. Eyenovia was founded in 2014.

Business identity

Contact email
[email protected]
Phone number
(917) 289-1117
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
2014-01-01, Year

Headquarters

Postal code
10017
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
13
Total equity funding
$107.5M
Last funding
Post IPO Equity / $50M / 2025-06-17
Last equity funding
Post IPO Equity / $50M
Investors
3
Lead investors
3
Founders
1
Articles
169
Exited on
2018-01-25

Founders and investors

Founders

Sean Ianchulev

Lead investors

Armistice CapitalAvenue Capital GroupSilicon Valley Bank

Investors

Armistice CapitalAvenue Capital GroupSilicon Valley Bank